Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellgram-LC
- Development stage
- Phase 3
- Lead developer
- Pharmicell
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Hepatic Artery Injection
01
Overview
Cellgram-LC is an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy developed by Pharmicell for the treatment of liver cirrhosis, specifically alcoholic liver cirrhosis. The therapy involves the extraction of bone marrow from the patient, followed by the isolation and ex vivo expansion of mesenchymal stem cells. These expanded cells are then administered back to the patient via hepatic artery injection. Once in the liver, the MSCs exert therapeutic effects through paracrine signaling, secreting various cytokines and growth factors such as hepatocyte growth factor (HGF) and interleukin-10 (IL-10). These factors help to inhibit the activation of hepatic stellate cells, which are the primary drivers of liver fibrosis, and promote the regeneration of hepatocytes. Cellgram-LC is designed to improve liver function and reduce the severity of fibrosis in patients with chronic liver disease.
- Brand names
- Cellgram-LC
- Other names
- autologous bone marrow-derived mesenchymal stem cellsPharmicell-LC
Beyond the preview
Go deeper on Cellgram-LC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellgram-LC.